TVRD

Tvardi Therapeutics Inc

4.55

0.32+7.57%

After Hours: 4.417 -0.13 -2.93%19:13 01/09 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE4.250/4.230

TODAY RANGE4.010-4.700

VOL302.19K

MARKET CAP42.69M

52 WEEK RANGE3.740-43.65

AVG VOL (3M)337.22K

% TURNOVER3.22%

TURNOVER--

P/E (TTM)-0.5446

% RANGE16.31%

EPS(TTM)-8.3552

P/E(FORWARD)-3.1597

P/B1.531

BVPS2.971

DIVIDEND--

P/S0.9714

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP26.98M

SHARES OUTSTANDING9.38M

NEXT EARNINGS03/09-03/13

FREE FLOAT5.93M

LOT SIZE1

EX-DATE04/16/2025

News

Press Releases

Financial Reports

Profile

TipRanks·14h ago
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Anika Therapeutics (ANIK)
Reuters·1d ago
Tvardi Therapeutics Reports Positive Phase 2 Results for TTI-101 in IPF Trial
TipRanks·1d ago
Tvardi Therapeutics announces further Phase 2 REVERT IPF data
Reuters·1d ago
TVARDI THERAPEUTICS INC - TOPLINE HEALTHY VOLUNTEER DATA FROM PHASE 1 STUDY OF NEXT-GENERATION STAT3 INHIBITOR, TTI-109, ON TRACK FOR H1 2026
Reuters·1d ago
Tvardi Therapeutics Reports Phase 2 Data Showing TTI-101 Reduces Fibrosis in IPF Patients
Reuters·12/18/2025 22:21
Tvardi Therapeutics Approves New Severance and Retention Compensation Plan for Executives
TipRanks·11/21/2025 17:45
Tvardi Therapeutics: Buy Rating Reaffirmed Amid Upcoming Catalysts and Risk-Reward Scenario
TipRanks·11/19/2025 11:58
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials
Reuters·11/18/2025 13:03
Tvardi Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
TipRanks·11/16/2025 06:00
Tvardi Therapeutics Faces Financial Hurdles Amidst Ongoing Product Development Challenges
TipRanks·11/15/2025 17:26
Promising Pipeline and Financial Stability Drive Buy Rating for Tvardi Therapeutics
TipRanks·11/14/2025 13:37
Cantor Fitzgerald Remains a Hold on Tvardi Therapeutics (TVRD)
TipRanks·11/14/2025 09:06
Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD)
Seeking Alpha·11/13/2025 21:38
Tvardi Therapeutics GAAP EPS of -$0.59 beats by $0.22
Reuters·11/13/2025 21:02
Tvardi Therapeutics reports third quarter 2025 results and updates on clinical programs

Same Industry

Name/Symbol

Change%

Price

Tvardi Therapeutics Inc

TVRD

+7.57%

4.55

Regeneron Pharmaceuticals

REGN

-0.56%

796.55

GridAI Tech

GRDX

+3.32%

4.67

BIONTECH

BNTX

+1.01%

99.85

United Therapeutics Corp.

UTHR

-1.55%

483.23

Vertex Pharmaceuticals Inc

VRTX

-1.24%

463.86

Siga Technologie

SIGA

-2.36%

6.61

Moderna

MRNA

+1.30%

34.30

Charles Riv Labs Intl Inc

CRL

+2.51%

220.91

Medpace Holdings

MEDP

-0.84%

595.00

Talphera Inc

TLPH

-2.75%

1.06

ICON PLC

ICLR

-3.63%

181.38

China Biologic

CBPO

119.99

Iqvia Hldgs Inc

IQV

-0.32%

242.41

MOLECULAR PARTNERS AG

MOLN

-3.53%

4.10

Arcturus Therape

ARCT

+0.15%

6.78

Gilead Sciences Inc

GILD

+0.36%

121.10

PRA Health

PRAH

165.21

Incyte Corp

INCY

+0.90%

106.87

Aptevo Therapeutics Inc

APVO

+5.00%

9.66

Biospecifics

BSTC

+0.15%

88.53

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.